Aura Biosciences raises ~$280.8M in public offering; to repurchase $39M in stock from Matrix Capital

Aura Biosciences, Inc.

Offering of 39,591,000 shares at $6.00 and 3,800,000 pre-funded warrants, net proceeds ~$280.8M.
Underwriters' option for additional 6,508,650 shares exercised in full.
$241.8M to advance clinical programs including bel-sar and early choroidal melanoma.
$39M to repurchase 6,922,870 shares from Matrix Capital at $5.64 per share.
Cash runway extended into second half of 2028.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aura Biosciences, Inc. entered into Underwriting Agreement with Leerink Partners LLC, TD Securities (USA) LLC and Evercore Group L.L.C., as representatives of the several underwriters (effective 2026-05-04).

Action: entry
Agreement: underwriting
Counterparty: Leerink Partners LLC, TD Securities (USA) LLC and Evercore Group L.L.C., as representatives of the several underwriters
Effective: 2026-05-04

Exact text from the filing

On May 4, 2026, Aura Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering

View on SEC.gov

Browse all material agreements →

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-206804

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.